Glaxo in £244m deal with Oxford BioTherapeutics
Management and investors in small biotechnology group Oxford BioTherapeutics (OBT) have secured a huge boost in resources after agreeing a £244m deal with GlaxoSmithKline, the UK's largest drug group.

For the full story as seen in the Telegraph visit: Oxford BioTherapeutics full story.

Oxford BioTherapeutics
Website: www.oxbt.co.uk
Location: Oxfordshire
Date of first investment: January 2007
Amount invested to date: £1,600,000
Catapult contact: Jonathan Earl

Oxford BioTherapeutics (OBT) applies its integrated proteomics platform for the discovery and development of diagnostic and therapeutic products. OBT has the world’s largest database of biomarkers for protein based disease. The company is at the forefront of new developments in personalised medicine, being enabled by the mapping of the human genome. The company has developed a unique integrated platform that combines genomic, proteomic and clinical information to accelerate the discovery and validation of drug targets and biomarkers in human beings. The benefits are improved biomarkers for patient selection, drug response and efficacy monitoring, and the integration of diagnostics into drug development and product launch, thereby facilitating more accurate drug development and providing cost and time savings. OBT works closely with Biosite, Medarex and Amgen, with whom it has collaboration agreements for exploitation of this technology. Non Executive Directors on the Board include Elliott Forster, VP of Development at Pfizer, and Jeff Warren, formerly CEO of Bristol & West plc.

> Download Tombstone